Design, synthesis, and antiproliferative activities of novel thiazolyl-pyrazole hybrid derivatives

被引:7
作者
Kuzu, Burak [1 ]
Erguc, Ali [2 ]
Karakus, Fuat [3 ]
Arzuk, Ege [4 ]
机构
[1] Van Yuzuncu Yil Univ, Fac Pharm, Dept Pharmaceut Chem, TR-65080 Van, Turkiye
[2] Izmir Katip Celebi Univ, Fac Pharm, Dept Pharmaceut Toxicol, TR-35620 Van, Turkiye
[3] Van Yuzuncu Yil Univ, Fac Pharm, Dept Pharmaceut Toxicol, TR-65080 Van, Turkiye
[4] Ege Univ, Fac Pharm, Dept Pharmaceut Toxicol, TR-35040 Izmir, Turkiye
关键词
Thiazolyl-pyrazole; Antiproliferation; ADMET; SAR; BIOLOGICAL EVALUATION; MOLECULAR DOCKING; ANTICANCER; INHIBITORS; DISCOVERY; POTENT;
D O I
10.1007/s00044-023-03090-2
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In this study, a series of derivatives of thiazolyl-pyrazole hybrid structures were designed to search for new heterocyclic compound-based antitumor agents. The designed target structures were synthesized with easy, practical, and efficient procedures. The antiproliferative effect of the synthesized compounds against cancer cell lines A549, MCF-7, and HepG2 was evaluated regarding inhibition concentration and selectivity index against healthy cell line CCD-34Lu. The results overall showed that the compounds had high antiproliferation against cancer cells compared to the doxorubicin-positive control. In particular, compound 11 A549 (SI: 3.58) and HepG2 (SI: 12.36) had high selectivity in cancer cell lines, while compounds 10h and 10o had high selectivity (SI: 10.74 for both) in MCF-7 cancer cell lines. The calculated theoretical pharmacokinetic properties revealed that they could be suitable drug candidates. In addition, in vitro test results indicate a correlation between the structure-activity relationships of the compounds. The various molecular modifications of thiazolyl-pyrazole hybrid compounds are promising for developing new anticancer drug candidates.
引用
收藏
页码:1690 / 1700
页数:11
相关论文
共 30 条
[1]   Heterocyclic Scaffolds: Centrality in Anticancer Drug Development [J].
Ali, Imran ;
Lone, Mohammad Nadeem ;
Al-Othman, Zeid A. ;
Al-Warthan, Abdulrahman ;
Sanagi, Mohd Marsin .
CURRENT DRUG TARGETS, 2015, 16 (07) :711-734
[2]  
Altintop MD, 2014, LETT DRUG DES DISCOV, V11, P833
[3]   ProTox-II: a webserver for the prediction of toxicity of chemicals [J].
Banerjee, Priyanka ;
Eckert, Andreas O. ;
Schrey, Anna K. ;
Preissner, Robert .
NUCLEIC ACIDS RESEARCH, 2018, 46 (W1) :W257-W263
[4]   Evaluation of Substituted Pyrazole-Based Kinase Inhibitors in One Decade (2011-2020): Current Status and Future Prospects [J].
El-Gamal, Mohammed I. ;
Zaraei, Seyed-Omar ;
Madkour, Moustafa M. ;
Anbar, Hanan S. .
MOLECULES, 2022, 27 (01)
[5]   Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation [J].
Furet, Pascal ;
Guagnano, Vito ;
Fairhurst, Robin A. ;
Imbach-Weese, Patricia ;
Bruce, Ian ;
Knapp, Mark ;
Fritsch, Christine ;
Blasco, Francesca ;
Blanz, Joachim ;
Aichholz, Reiner ;
Hamon, Jacques ;
Fabbro, Doriano ;
Caravatti, Giorgio .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (13) :3741-3748
[6]   Antiproliferative activity of thiazole and oxazole derivatives: A systematic review of in vitro and in vivo studies [J].
Guerrero-Pepinosa, Nancy Y. ;
Cardona-Trujillo, Maria C. ;
Garzon-Castano, Sandra C. ;
Veloza, Luz Angela ;
Sepulveda-Arias, Juan C. .
BIOMEDICINE & PHARMACOTHERAPY, 2021, 138
[7]  
Indrayanto G, 2021, PROF DRUG SUB EXCIP, V46, P273, DOI 10.1016/bs.podrm.2020.07.005
[8]   Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph plus Acute Lymphoblastic Leukaemia [J].
Keating, Gillian M. .
DRUGS, 2017, 77 (01) :85-96
[9]   An easy synthetic protocol for imidazo-1,4-oxazines and evaluation of their toxicities [J].
Kuzu, Burak ;
Genc, Hasan ;
Taspinar, Mehmet ;
Tan, Meltem ;
Menges, Nurettin .
HETEROATOM CHEMISTRY, 2018, 29 (01)
[10]   Tandem Synthesis of Novel thiazole-substituted pyrrolo[1,2-d][1,2,4]triazin-4(3H)-one Derivatives and their Theoretical Pharmacokinetic Profiles [J].
Kuzu, Eylem ;
Kuzu, Burak .
CHEMISTRY OF HETEROCYCLIC COMPOUNDS, 2023, 59 (1-2) :80-87